Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excessive amounts of lipid droplet in the liver, which is closely related to obesity, type 2 diabetes, and metabolic syndrome. The primary pathophysiological factor cont...
Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excessive amounts of lipid droplet in the liver, which is closely related to obesity, type 2 diabetes, and metabolic syndrome. The primary pathophysiological factor contributing to NAFLD is the elevation in fatty acid biosynthesis resulting from carbohydrate intake. Specifically, excessive fructose consumption transforms carbohydrates into triglycerides via fatty acids through de novo lipogenesis in the liver, leading to their accumulation and subsequent lipid buildup. Moreover, excessive fructose intake enhances intestinal permeability, increasing the secretion of pro-inflammatory factors that contribute to both liver lipid accumulation and intestinal inflammation. The progression of NAFLD to non-alcoholic steatohepatitis occurs when liver lipids accumulate, exacerbating the inflammatory response. Hence, it is crucial to mitigate both inflammatory response and hepatic lipid accumulation to effectively prevent NAFLD.
Probiotics and postbiotics play a crucial role in enhancing various health functions of the host by modulating the intestinal flora. Recent research has presented findings on the efficacy of specific strains in mitigating NAFLD. This study explored the potential of two recently isolated strains to attenuate pro-inflammatory factors in human intestinal epithelial cells (HT- 29) stimulated by lipopolysaccharide (LPS). The study verified that the two recently isolated strains exhibited a comparable ability to suppress the inflammatory response when compared to Lactiplantibacillus plantarum and Lactobacillus rhamnosus, both of which were previously acknowledged for their anti-inflammatory effects.
Furthermore, the efficacy of suppressing hepatic lipid accumulation was validated in NAFLD-induced mice fed with high-fat and high-fructose diet. Serum analysis revealed a significant reduction in triglycerides and total cholesterol in the groups receiving the two probiotics compared to the control group. Moreover, the liver weight divided by body weight exhibited a noteworthy decrease in the probiotics intake group compared to the control group. Histological analysis of the liver further confirmed the substantial inhibition of lipid accumulation by probiotics. These findings affirm that the newly isolated probiotics effectively suppress lipid accumulation in the liver in NAFLD-induced mice. In summary, the two newly isolated strains demonstrate efficacy in preventing NAFLD by attenuating inflammatory responses in human intestinal epithelial cells and inhibiting lipid accumulation in the liver of mice.